Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Information source: Centre Leon Berard
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Thyroid Carcinoma
Intervention: Continuous pazopanib (Arm A) (Drug); Intermittent pazopanib (Arm B) (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: Centre Leon Berard Official(s) and/or principal investigator(s): Christelle De La Fouchardière, MD, Principal Investigator, Affiliation: Centre Léon Bérard; Lyon
Overall contact: Julien Gautier, Phone: +33426556829, Email: julien.gautier@lyon.unicancer.fr
Summary
The objective of this study is to determine the feasibility of pazopanib treatment
interruption with reintroduction at progression in iodine refractory progressive
Differentiated Thyroid Cancer (DTC) patients as compared to pazopanib continuous
administration.
Clinical Details
Official title: A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Time to treatment failure (TTF)
Secondary outcome: Objective Response Rate (ORR)Disease Control Rate (DCR) Progression-Free Survival (PFS) Best response rate Duration of response Overall Survival (OS) Objective Response Rate (ORR) Disease Control Rate (SDR) Safety profile of pazopanib Quality of Life (QoL)
Detailed description:
Total or near-total thyroidectomy is the primary treatment for differentiated thyroid
carcinoma. Postoperatively, DTC are treated with radioiodine (131I) and thyroid stimulating
hormone (TSH) suppressive levothyroxine therapy.
But 5% to 20% of patients with DTC develop distant metastases; some of them become
refractory to 131I therapy.
Targeted therapies have been studied in iodine refractory DTC for several years but none of
these treatments has yet been approved in DTC and clinicians continue to enroll patients in
clinical trials. The agents used so far in thyroid cancer are small molecules sharing the
property to inhibit various tyrosine kinase receptors such as Vascular Endothelial Growth
Factor Receptor (VEGFR), Epidermal Growth Factor Receptor (EGFR), RET or c-met.
The VEGF (Vascular Endothelial Growth Factor) is one of the several pro angiogenic molecules
that play a pivotal role in angiogenesis, one of the mechanisms involved in tumor growth and
dissemination.
VEGF expression is highly prevalent in Papillary Thyroid Carcinoma (PTCs) (79%), Follicular
Thyroid Carcinoma (FTCs) (50%) or Poorly Differentiated Thyroid Carcinoma (PDTCs) (37%) and
VEGFR is respectively expressed in 76%, 83% and 25% for VEGRF-1 and 68%, 56% and 37% for
VEGRF-2.
Pazopanib (GW786034 - GlaxoSmithKline) is an orally administered, potent multitarget
tyrosine kinase inhibitor of VEGFR in particular (but also of PDGFR-α and - β, and stem cell
factor receptor c-Kit).
The results obtained in metastatic or locally advanced refractory DTC are currently
available (phase II study of 39 patients with metastatic, rapidly progressive RAI-refractory
DTC, treated with pazopanib 800mg daily, were published in Lancet Oncology in 2010 by KC
Bible), demonstrating the efficacy of these therapies in this indication. However, no clear
data is yet available indicating the optimal duration of treatment in first line therapy:
patients are currently treated until progression or until drug discontinuation due to
toxicity. Indeed, patients may have some difficulties to manage the chronic mild to moderate
(grade 1-2) side-effects related to long-term treatment, leading some asymptomatic patients
in whom tumor is controlled by TKI treatment to ask for treatment interruption.
The intermittent administration should avoid the occurrence of long-term adverse event and
subsequent dose reductions or discontinuation, thus allowing a longer control of underlying
disease.
All these considerations led our reflexion in the design of the present study, that is to
say to determine the feasibility of pazopanib treatment interruption with reintroduction at
progression in iodine refractory progressive DTC patients as compared to pazopanib
continuous administration, after 6 initial cycles of pazopanib 800 mg daily for all patients
included in the study, with a strong rationale for intermittent administration of pazopanib.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age ≥ 18 years old,
- Histologically confirmed diagnosis of differentiated thyroid cancer (papillary,
follicular and poorly differentiated)
- Archival tumor sample available. It will be provided for all subjects, for biomarker
analysis before and/or during study treatment.
- Patients must have been treated with therapeutic RAI. Patients may have received
prior treatment with either 1 line of chemotherapy and/or up to 1 Tyrosine Kinase
Inhibitor,
- Resistance to therapeutic radioiodine (RAI) (for DTC) as demonstrated at least by one
of the following:
- Absence of iodine uptake in at least one target lesion on a post-therapy
radioactive iodine scan,
- Presence of a target lesion after a cumulative radio-iodine activity of at least
600 mCi,
- Patient with uptake who have RAI treatment of at least 100 mCi within the last
12 months and have disease progression,
- Documented progression as per RECIST 1. 1 based on 2 consecutives imaging performed
within the last 12 months,
- Measurable disease according to RECIST version 1. 1,
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1,
- Adequate organ system function defined as the following:
Hematology:
- Absolute Neutrophils Count (ANC) ≥ 1. 5 Gi/L
- Hemoglobin ≥ 9 g/dL (5. 6µM) (transfusion is not allowed within 7 days of screening
assessments)
- Platelets ≥ 100 Gi/L
- Prothrombin Time (PT) ≤ 1. 2 x ULN or International Normalized Ratio (INR) ≤ 1. 2
Subjects receiving anticoagulant therapy are eligible if their INR is stable and
within the recommended range for the desired target of anticoagulation
- Activated Partial Thromboplastin Time (aPTT) ≤ 1. 2 x ULN
Electrolytes :
- Potassium within normal ranges.
Hepatic :
- Total bilirubin ≤ 1. 5 x ULN
- Alanine AminoTansferase (ALAT) and Aspartate AminoTransferase (ASAT) ≤ 2. 5 x ULN
Concomitant elevation in bilirubin and ASAT/ALAT above 1. 0xULN is not allowed
Renal :
- Serum creatinine ≤ 1. 5 mg/dL (133µM) or if serum creatinine> 1. 5 mg/dL, calculated
creatinine clearance (ClCR) ≥ 50 mL/min (Cockcroft formula or MDRD formula for
patients older than 65 years old)
- Urine Protein to Creatinine Ratio (UPC) < 1; If UPC ratio ≥ 1, then a 24-hour urine
protein must be assessed. Subjects must have a 24-hour urine protein value < 1 gram
to be eligible Use of urine dipstick for renal function assessment is not acceptable
- Women of childbearing potential must have a negative urine or serum pregnancy
test within 7 days of first dose of pazopanib. They must be willing to use
effective contraception methods during the study and up to 7 days after the last
pazopanib administration.
- Affiliated to the French social security system.
- Subjects must provide written informed consent prior to perform any
study-specific procedure or assessment and must be willing to comply with
treatment and follow up.
Note: Procedures conducted as part of the subject's routine clinical management (e. g.,
blood count, imaging study such as bone scan) and obtained prior to signing of informed
consent may be utilized for screening or baseline purposes provided these procedures are
conducted as specified in the protocol,
Exclusion Criteria:
- Other histological sub-types of thyroid tumors like medullar carcinoma, anaplastic
carcinoma, lymphoma or sarcoma,
- Prior treatment with pazopanib,
- Prior malignancy, Subjects who have had another malignancy and have been disease-free
for 5 years, or subjects with a history of completely resected non-melanomatous skin
carcinoma or successfully treated in situ carcinoma are eligible
- Symptomatic metastases of Central nervous system (CNS) requiring or having required
steroids or enzyme-inducing anticonvulsants within 4 weeks before inclusion ,
- Clinically significant gastrointestinal abnormalities that may increase the risk for
gastrointestinal bleeding including, but not limited to:
- Active peptic ulcer disease,
- Known intraluminal metastatic lesion with risk of bleeding,
- Inflammatory bowel disease (e. g. ulcerative colitis, Crohn's disease), or other
gastrointestinal conditions with increased risk of perforation,
- History of abdominal fistula, gastrointestinal perforation, or intra abdominal
abscess within 28 days prior to begin study treatment,
- Clinically significant gastrointestinal abnormalities that may affect absorption of
investigational product including, but not limited to:
- Malabsorption syndrome,
- Major resection of the stomach or small bowel,
- Corrected QT interval (QTc) > 480 msec (correction method according to the Bazett's
method),
- History of any one or more of the following cardiovascular conditions within the past
6 months :
- Cardiac angioplasty or stenting,
- Myocardial infarction,
- Unstable angina,
- Coronary artery bypass graft surgery,
- Symptomatic peripheral vascular disease,
- Class III or IV congestive heart failure, as defined by the New York Heart
Association (NYHA),
- Cerebrovascular accident including Transient Ischemic Attack (TIA), pulmonary
embolism or untreated Deep Venous Thrombosis (DVT), Subjects with recent DVT who
have been treated with therapeutic anti-coagulating agents for at least 6 weeks
are eligible,
- Poorly controlled hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood
pressure ≥ 90 mmHg) as described in the section 7. 2 "Study requirements" of this
protocol, Initiation or adjustment of antihypertensive medication(s) is permitted
prior to study entry. At least one day after antihypertensive medication initiation
or adjustment, blood pressure (BP) must be re-assessed three times at approximately
2-minute intervals. These three values should be averaged to obtain the mean
diastolic blood pressure and the mean systolic blood pressure. The mean SBP / DBP
ratio must be <140/90 mmHg (OR 150/90 mm Hg, if this criterion is approved by the
coordination center) in order to be eligible.
- Major surgery or trauma within 28 days prior to first dose of investigational product
and/or presence of any non-healing wound, fracture, or ulcer (procedures such as
catheter placement are not considered to be major surgery),
- Evidence of active bleeding or bleeding diathesis,
- Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that
increase the risk of pulmonary hemorrhage, Lesions infiltrating major pulmonary
vessels (contiguous tumor and vessels) are excluded; however, the presence of a tumor
that is touching, but not infiltrating (abutting) the vessels is acceptable (CT with
contrast is strongly recommended to evaluate such lesions).
- Large protruding endobronchial lesions in the main or lobar bronchi are
excluded; however, endobronchial lesions in the segmented bronchi are allowed.
- Lesions extensively infiltrating the main or lobar bronchi are excluded;
however, minor infiltrations in the wall of the bronchi are allowed.
- Hemoptysis within the last 8 weeks before inclusion,
- Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drug,
- Treatment with any of the following anti-cancer therapies :
- radiation therapy, surgery or tumor embolization within 14 days prior to the
first dose of pazopanib (analgesic radiation therapy is allowed if the radiation
field doesn't include a potential target lesion for tumor assessments),
- chemotherapy, immunotherapy, biologic therapy, investigational therapy or
hormonal therapy within 14 days or five half-lives of a drug (whichever is
longer) prior to the first dose of pazopanib,
- Administration of other oncologic drug or any non-oncologic investigational drug
within 30 days (or 5 half lives whichever is longer) prior to receiving the first
dose of study treatment, or planned to be administered during the study
participation,
- Unable or unwilling to discontinue use of prohibited medications listed in Section
6. 2.4. c "Prohibited medications" for at least 14 days or five half-lives of a drug
(whichever is longer) prior to the first dose of study drug and for the duration of
the study,
- Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is
progressing in severity (according to the NCI-CTC AE v4. 0), except alopecia,
- Any serious and/or unstable pre-existing medical, psychiatric, or other condition
that could interfere with subject's safety, provision of informed consent, or
compliance to study procedures.
Locations and Contacts
Julien Gautier, Phone: +33426556829, Email: julien.gautier@lyon.unicancer.fr
CHU Angers, Angers 49933, France; Recruiting Vincent ROHMER, MD, Principal Investigator Frédéric ILLOUZ, MD, Sub-Investigator Sandrine LABOUREAU-SOARES BARBOSA, MD, Sub-Investigator Patrice RODIEN, MD, Sub-Investigator
CHU Bordeaux, Bordeaux 33075, France; Recruiting Alain RAVAUD, MD, Principal Investigator Laurence DIGUE, MD, Sub-Investigator Marine GROSS-GOUPIL, MD, Sub-Investigator Amandine QUIVY, MD, Sub-Investigator Denis SMITH, MD, Sub-Investigator Nathalie TRUFLANDIER, MD, Sub-Investigator
Institut Bergonié, Bordeaux 33076, France; Recruiting Yann GODBERT, MD, Principal Investigator Françoise BONICHON, MD, Sub-Investigator Antoine ITALIANO, MD, Sub-Investigator
Centre François Baclesse, Caen 14076, France; Recruiting Stéphane BARDET, MD, Principal Investigator Renaud CIAPPUCCINI, MD, Sub-Investigator
CHRU Lille Hôpital Claude Huriez, Lille 59037, France; Recruiting Christine DOCAO, MD, Principal Investigator Maria-Claire MIGAUD, MD, Sub-Investigator
Centre Leon Berard, Lyon 69373, France; Recruiting Christelle DE LA FOUCHARDIERE, MD, Principal Investigator
Hôpital de la Timone APHM, Marseille 13385, France; Recruiting Patricia NICCOLI, MD, Principal Investigator Charlotte DUPUIS, MD, Sub-Investigator
Centre Antoine Lacassagne, Nice 06189, France; Recruiting Danielle BENISVY, MD, Principal Investigator Esma SAADA-BOUZID, MD, Sub-Investigator
Hôpital de la Pitié Salpêtrière APHP, Paris 75651, France; Recruiting Johanna WASSERMANN, MD, Principal Investigator Laurence LEENHARDT, MD, Sub-Investigator Jean-Philippe SPANO, MD, Sub-Investigator Camille BUFFET, MD, Sub-Investigator
Hôpital Saint-Louis APHP, Paris 75010, France; Recruiting Damien POUESSEL, MD, Principal Investigator Stéphane CULINE, MD, Sub-Investigator Marie-Elisabeth TOUBERT, MD, Sub-Investigator Cécile CHOUGNET, MD, Sub-Investigator
Institut Jean Godinot, Reims 51726, France; Recruiting Audrey DALAC, MD, Principal Investigator Sandrine FIEFFE-COQUET, MD, Sub-Investigator Jean-Marie POCHART, MD, Sub-Investigator Claire SCHVARTZ, MD, Sub-Investigator
Institut Claudius Régaud, Toulouse 31052, France; Recruiting Slimane ZERDOUD, MD, Principal Investigator Jean-Pierre DELORD, MD, Sub-Investigator
Institut Gustave Roussy, Villejuif 94805, France; Recruiting Sophie LEBOULLEUX, MD, Principal Investigator Eric BAUDIN, MD, Sub-Investigator Amandine BERDELOU, MD, Sub-Investigator Martin SCHLUMBERGER, MD, Sub-Investigator
Additional Information
Related publications: Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME, Rubin J, Sideras K, Morris JC 3rd, McIver B, Burton JK, Webster KP, Bieber C, Traynor AM, Flynn PJ, Goh BC, Tang H, Ivy SP, Erlichman C; Endocrine Malignancies Disease Oriented Group; Mayo Clinic Cancer Center; Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 2010 Oct;11(10):962-72. doi: 10.1016/S1470-2045(10)70203-5. Epub 2010 Sep 17. Altorki N, Lane ME, Bauer T, Lee PC, Guarino MJ, Pass H, Felip E, Peylan-Ramu N, Gurpide A, Grannis FW, Mitchell JD, Tachdjian S, Swann RS, Huff A, Roychowdhury DF, Reeves A, Ottesen LH, Yankelevitz DF. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non-small-cell lung cancer. J Clin Oncol. 2010 Jul 1;28(19):3131-7. doi: 10.1200/JCO.2009.23.9749. Epub 2010 Jun 1. Billemont B, Medioni J, Taillade L, Helley D, Meric JB, Rixe O, Oudard S. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer. 2008 Nov 4;99(9):1380-2. doi: 10.1038/sj.bjc.6604709. Epub 2008 Oct 7. Borson-Chazot F, Bardet S, Bournaud C, Conte-Devolx B, Corone C, D'Herbomez M, Henry JF, Leenhardt L, Peix JL, Schlumberger M, Wemeau JL; Expert Group for French Recommendations for the Management of Differentiated Thyroid Carcinomas of Vesicular Origin, Baudin E, Berger N, Bernard MH, Calzada-Nocaudie M, Caron P, Catargi B, Chabrier G, Charrie A, Franc B, Hartl D, Helal B, Kerlan V, Kraimps JL, Leboulleux S, Le Clech G, Menegaux F, Orgiazzi J, Perié S, Raingeard I, Rodien P, Rohmer V, Sadoul JL, Schwartz C, Tenenbaum F, Toubert ME, Tramalloni J, Travagli JP, Vaudrey C. Guidelines for the management of differentiated thyroid carcinomas of vesicular origin. Ann Endocrinol (Paris). 2008 Dec;69(6):472-86. Review. Brose M. S., et al. Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. J Clin Oncol (meeting Abstracts) 27.15S (2009) : 6002. Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010 Nov 1;16(21):5260-8. doi: 10.1158/1078-0432.CCR-10-0994. Epub 2010 Sep 16. de la Fouchardiere C, Droz JP. Targeted therapies and thyroid cancer: an update. Anticancer Drugs. 2011 Aug;22(7):688-99. doi: 10.1097/CAD.0b013e32834319c7. Review. Fagin JA, Tuttle RM, Pfister DG. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. J Clin Endocrinol Metab. 2010 Jun;95(6):2621-4. doi: 10.1210/jc.2010-0800. GSK Laboratories. Investigator's Brochure of pazopanib, version 09 dated 25 Jan. 2012.Ref Type: Unpublished Work Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008 Oct 10;26(29):4714-9. doi: 10.1200/JCO.2008.16.3279. Epub 2008 Jun 9. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010 Jan 20;28(3):475-80. doi: 10.1200/JCO.2008.21.6994. Epub 2009 Dec 14. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982 Apr-Jun;1(2):121-9. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol. 2007 Aug;88(4):271-7. Iwamoto FM, Lamborn KR, Robins HI, Mehta MP, Chang SM, Butowski NA, Deangelis LM, Abrey LE, Zhang WT, Prados MD, Fine HA. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010 Aug;12(8):855-61. doi: 10.1093/neuonc/noq025. Epub 2010 Mar 3. Kaplan, E. L and P. Meier. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958): 457-81. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007 Jul;6(7):2012-21. Lan, K. K. G. and D. L. De Mets. Discrete sequential boundaries for clinical trials. Biometrika 70 (1983): 659-63 Leboulleux, S., Bastholt, L., and Krause TM. Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): a randomized, double-blind phase II trial. International Thyroid Conference;Paris, France; [ Sept 11.16, 2009. Abstr 0C.023.]. 2010. Ref Type: Abstract Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010 Aug 1;28(22):3562-9. doi: 10.1200/JCO.2009.26.9571. Epub 2010 Jul 6. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008 May;21 Suppl 2:S37-43. doi: 10.1038/modpathol.2008.10. Review. Pacini F, Castagna MG, Brilli L, Pentheroudakis G; ESMO Guidelines Working Group. Differentiated thyroid cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009 May;20 Suppl 4:143-6. doi: 10.1093/annonc/mdp156. Review. Prince HM, Hönemann D, Spencer A, Rizzieri DA, Stadtmauer EA, Roberts AW, Bahlis N, Tricot G, Bell B, Demarini DJ, Benjamin Suttle A, Baker KL, Pandite LN. Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034). Blood. 2009 May 7;113(19):4819-20. doi: 10.1182/blood-2009-02-207209. Ravaud, A., et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol (Meeting Abstracts) 26.15_suppl (2008): 6058. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009 Jun 1;69(11):4885-93. doi: 10.1158/0008-5472.CAN-09-0727. Schlumberger M. [Papillary and follicular thyroid carcinoma]. Ann Endocrinol (Paris). 2007 Jun;68(2-3):120-8. Epub 2007 Jun 19. Review. French. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 3;359(1):31-42. doi: 10.1056/NEJMoa075853. Slamon D,. et al. Pazopanib + Lapatinib is more active than Lapatinib alone : Updated results from a randomized study in patients with first-line ErbB2-positive advanced or metastatic breast cancer [ESMO abstract 139P]. Ann Oncol. 2008c ;19 (supp 8) : viii 64-65. Sleijfer, S., et al. Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043. ASCO Meeting Abstracts 25.18_suppl (2007): 10031. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010 Feb 20;28(6):1061-8. doi: 10.1200/JCO.2009.23.9764. Epub 2010 Jan 25. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab. 1997 Nov;82(11):3741-7. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M, Nikiforov YE. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009 Dec;94(12):4735-41. doi: 10.1210/jc.2009-1233. Epub 2009 Oct 16.
Starting date: March 2013
Last updated: May 7, 2015
|